The results showed that the inactivation of KRAS using KRAS siRNA and statins and inhibition of CXCR1/2 by reparixin dramatically inhibited the expression of OA-induced EMT markers (Figure 7A and Figure S4A), followed by a reduction in OA-promoted CRC cell invasive ability (Figure 7B and Figure S4B). The gene discussed is KRAS; the disease is colorectal carcinoma.